The BRAF inhibitors vemurafenib [7] and dabrafenib [8] were first approved as single agents by the Food and Drug Administration (FDA) for the treatment of BRAF-mutated unresectable or metastatic melanoma. The gene discussed is BRAF; the disease is metastatic melanoma.